Marc Lemonnier, Ph.D., Founder and Chief Executive Officer
Marc is the CEO and co-founder of Antabio and a member of the Board of the European Alliance of Biopharmaceutical companies combating Anti-Microbial resistance (BEAM Alliance). A molecular microbiologist by training, Marc is the author of numerous peer-reviewed articles in the field of pathogenic bacterial infections and their biology. Prior to founding Antabio, Marc held different research positions at various institutions globally such as CNRS and Inserm (France), CSIC (Spain) and Emory University (USA). At Antabio, Marc structured the corporate and financial aspects of the company and successfully managed Antabio’s fundraisings using different strategies including innovative tools such as crowdfunding (Antabio being the world-premier crowdfunding exit for a biotech start-up). Under Marc’s leadership, ANTABIO has attracted low double-digit million funding and received numerous awards including the BIOVISION Investment Conference Award (2016), the “Concours Mondial de l’Innovation” Worldwide Innovation Challenge (2014), and two Seeding Drug Discovery Awards from the Wellcome Trust (2013 and 2015).
Martin Everett, Ph.D., Chief Scientific Officer
Martin has over 25 years’ experience in academia, pharmaceutical R&D (GSK) and biotechnology (MerLion, ANTABIO) as a drug discovery scientist with a particular interest in antibiotic resistance/persistence mechanisms. At GSK he managed a high-throughput screening group and led several lead discovery projects. At MerLion he was Head of Research leading a multi-disciplinary team discovering novel natural product derived compounds. At ANTABIO, Martin leads the internal discovery group, and has responsibility for external research collaborations. He is Principal Investigator for ANTABIO’s Pseudomonas biofilms inhibitors programme, supported by a Wellcome Trust Seeding Drug Discovery Award.
David Davies, Ph.D., Head of Medicinal Chemistry
David has over 25 years of experience in medicinal chemistry within the pharmaceutical industry (GSK) most of which are in the discovery of antibiotic drugs for clinical use and potentially biodefense. Prior to ANTABIO, David has worked with biotech companies in the antibacterial arena (Prolysis, Biota) in support of their strategy and medicinal chemistry efforts while simultaneously holding a part-time academic position in the Chemistry Department of University College London (UCL). David is an inventor on about 30 patents, most of them in the antibacterial area. His past antibacterial projects were supported by the Wellcome Trust and the DTRA (US Defense Threat Reduction Agency) as well as internal GSK projects. At present he is the Project Manager of ANTABIO’s metallo β-lactamases inhibitors programme, supported by a Wellcome Trust Seeding Drug Discovery Award, with chemists in the UK and India.
Magdalena Zalacain, Ph.D., Head of Preclinical Development
Magda has over 20 years’ experience in antibacterial drug discovery in the pharmaceutical industry (GSK) with proven ability to progress antibacterial efforts from target identification to clinical trials. While at GSK, she led the microbiology group with responsibility for all in vitro assays relating to antibacterial programs. In addition she lead several early stage programmes, from target identification to lead optimization, and one late stage project on peptide deformylase inhibitors that delivered a compound that reached Phase II clinical trials. During the last four years she has been an antibacterial drug discovery. At ANTABIO, Magda will coordinate the team’s activities and work with the relevant CROs to progress all preclinical studies.